Patents by Inventor Jeffrey M. Greve

Jeffrey M. Greve has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5686581
    Abstract: The present invention relates to novel forms and configurations of intercellular adhesion molecule (ICAM) including multimeric configurations that effectively bind to human rhinovirus and can effectively reduce HRV infectivity. When in a multimeric configuration, preferably as dimers, these proteins display enhanced binding of HRV and are able to reduce HRV infectivity as well as the infectivity of other viruses known to bind to the "major" group human rhinovirus receptor (HRR). The multimerized proteins may also be used to block tICAM interaction with lymphocyte function-associated antigen-1 (LFA-1).
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: November 11, 1997
    Assignee: Bayer Corporation
    Inventors: Jeffrey M. Greve, Alan McClelland
  • Patent number: 5674982
    Abstract: The present invention relates to novel forms and configurations of intercellular adhesion molecule (ICAM) including multimeric configurations that effectively bind to human rhinovirus and can effectively reduce HRV infectivity. When in a multimeric configuration, preferably as dimers, these proteins display enhanced binding of HRV and are able to reduce HRV infectivity as well as the infectivity of other viruses known to bind to the "major" group human rhinovirus receptor (HRR). The multimerized proteins may also be used to block tICAM interaction with lymphocyte function-associated antigen-1 (LFA-1).
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: October 7, 1997
    Assignee: Bayer Corporation
    Inventors: Jeffrey M. Greve, Alan McClelland
  • Patent number: 5589453
    Abstract: A water soluble human rhinovirus (HRV) major receptor preparation comprising detergent-complexed glycoprotein isolated from animal cells, preferably mammalian cells, that express the HRV major receptor and which exhibits the ability to bind to HRV capsids to substantially reduce infectivity of the virus. The purified, water soluble receptor is obtained by extracting cells expressing the receptor with detergent and isolating the solubilized detergent-glycoprotein complexes by binding to monoclonal antibody selective for the HRV receptor protein. Human rhinovirus receptor protein has subsequently been discovered by Greve et al. to be ICAM-1.
    Type: Grant
    Filed: September 30, 1994
    Date of Patent: December 31, 1996
    Assignee: Molecular Therapeutics, Inc.
    Inventor: Jeffrey M. Greve
  • Patent number: 5235049
    Abstract: The present invention relates to a soluble form of intercellular adhesion molecule (sICAM-1) and purified and isolated human sICAM-1. This invention also relates to a purified and isolated DNA sequence encoding sICAM-1. The extracellular domain of sICAM-1 and insoluble ICAM-1 are substantially the same. ICAM-1 is involved in the process through which lymphocytes attach to cellular substrates during inflammation and serves as the major human rhinovirus receptor (HRR). sICAM-1 therefore has both the property of reducing immune inflammation and inhibiting infection of rhinovirus and Coxsackie A virus.
    Type: Grant
    Filed: January 24, 1989
    Date of Patent: August 10, 1993
    Assignee: Molecular Therapeutics, Inc.
    Inventors: Alan McClelland, Jeffrey M. Greve